465 related articles for article (PubMed ID: 15288225)
1. Assessment of menstrual blood loss in Brazilian users of the frameless copper-releasing IUD with copper surface area of 330 mm2 and the frameless levonorgestrel-releasing intrauterine system.
Andrade AT; Souza JP; Andrade GN; Rowe PJ; Wildemeersch D
Contraception; 2004 Aug; 70(2):173-7. PubMed ID: 15288225
[TBL] [Abstract][Full Text] [Related]
2. Assessment of menstrual blood loss in Belgian users of the frameless copper-releasing IUD with copper surface area of 200 mm2 and users of a copper-levonorgestrel-releasing intrauterine system.
Wildemeersch D; Rowe PJ
Contraception; 2004 Aug; 70(2):169-72. PubMed ID: 15288224
[TBL] [Abstract][Full Text] [Related]
3. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
Wildemeersch D; Schacht E
Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
[TBL] [Abstract][Full Text] [Related]
4. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
[TBL] [Abstract][Full Text] [Related]
5. Menstrual blood loss in women using the frameless FibroPlant LNG-IUS.
Andrade A; Wildemeersch D
Contraception; 2009 Feb; 79(2):134-8. PubMed ID: 19135571
[TBL] [Abstract][Full Text] [Related]
6. Review of clinical experience with the frameless LNG-IUS for contraception and treatment of heavy menstrual bleeding.
Wildemeersch D; Andrade A
Gynecol Endocrinol; 2010 May; 26(5):383-9. PubMed ID: 20192899
[TBL] [Abstract][Full Text] [Related]
7. Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
Wildemeersch D; Schacht E; Wildemeersch P
Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):192-8. PubMed ID: 11848648
[TBL] [Abstract][Full Text] [Related]
8. Assessment of menstrual blood loss in Belgian users of a new T-shaped levonorgestrel-releasing intrauterine system.
Wildemeersch D; Rowe PJ
Contraception; 2005 Jun; 71(6):470-3. PubMed ID: 15914139
[TBL] [Abstract][Full Text] [Related]
9. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
[TBL] [Abstract][Full Text] [Related]
10. Assessment of menstrual blood loss in women with ideopathic menorrhagia using the frameless levonorgestrel-releasing intrauterine system.
Wildemeersch D; Rowe PJ
Contraception; 2004 Aug; 70(2):165-8. PubMed ID: 15288223
[TBL] [Abstract][Full Text] [Related]
11. Intrauterine devices. The optimal long-term contraceptive method?
Fortney JA; Feldblum PJ; Raymond EG
J Reprod Med; 1999 Mar; 44(3):269-74. PubMed ID: 10202746
[TBL] [Abstract][Full Text] [Related]
12. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
[TBL] [Abstract][Full Text] [Related]
13. Use of frameless intrauterine devices and systems in young nulliparous and adolescent women: results of a multicenter study.
Wildemeersch D; Jandi S; Pett A; Nolte K; Hasskamp T; Vrijens M
Int J Womens Health; 2014; 6():727-34. PubMed ID: 25125987
[TBL] [Abstract][Full Text] [Related]
14. Selection and performance of the levonorgestrel-releasing intrauterine system.
Lähteenmäki P; Bardin CW; Elomaa K; Haukkamaa M; Kivijärvi A; Kuukankorpi A; Venhola M; Tuominen J
Acta Obstet Gynecol Scand Suppl; 1997; 164():69-74. PubMed ID: 9225643
[TBL] [Abstract][Full Text] [Related]
15. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
Suvisaari J; Lähteenmäki P
Contraception; 1996 Oct; 54(4):201-8. PubMed ID: 8922872
[TBL] [Abstract][Full Text] [Related]
16. The levonorgestrel-releasing intrauterine device.
Toivonen J
Adv Contracept Deliv Syst; 1994; 10(3-4):191-8. PubMed ID: 12287838
[TBL] [Abstract][Full Text] [Related]
17. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
Modesto W; Bahamondes MV; Bahamondes L
Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
[TBL] [Abstract][Full Text] [Related]
18. Intrauterine devices: an effective alternative to oral hormonal contraception.
Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
[TBL] [Abstract][Full Text] [Related]
19. New frameless and framed intrauterine devices and systems - an overview.
Wildemeersch D
Contraception; 2007 Jun; 75(6 Suppl):S82-92. PubMed ID: 17531623
[TBL] [Abstract][Full Text] [Related]
20. [Menstrual blood loss and body iron stores: comparative study between a Multiload-375 IUD and a levonorgestrel vaginal ring].
Souza JP; Andrade AT; Pizarro E
Bol Cent Biol Reprod; 1991; 10(1):26-32. PubMed ID: 12318141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
